• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    2/13/24 8:06:00 AM ET
    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email

    Gainers

    • KalVista Pharma (NASDAQ:KALV) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $729.1 million.
    • Jin Medical International (NASDAQ:ZJYL) stock moved upwards by 25.75% to $10.45. The company's market cap stands at $1.6 billion.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 21.37% to $1.76. The market value of their outstanding shares is at $4.6 million.
    • Iterum Therapeutics (NASDAQ:ITRM) stock increased by 21.01% to $1.9. The market value of their outstanding shares is at $25.5 million.
    • Modular Medical (NASDAQ:MODD) shares rose 17.85% to $1.65. The market value of their outstanding shares is at $35.0 million.
    • MediciNova (NASDAQ:MNOV) stock moved upwards by 16.91% to $1.59. The market value of their outstanding shares is at $77.9 million.

    Losers

    • Sientra (NASDAQ:SIEN) stock decreased by 51.3% to $0.29 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.4 million.
    • G1 Therapeutics (NASDAQ:GTHX) shares fell 43.98% to $2.51. The market value of their outstanding shares is at $130.1 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares fell 17.39% to $0.94. The company's market cap stands at $2.9 million.
    • Syra Health (NASDAQ:SYRA) shares fell 12.02% to $2.93. The market value of their outstanding shares is at $18.8 million.
    • Beyond Air (NASDAQ:XAIR) shares declined by 11.17% to $1.91. The market value of their outstanding shares is at $68.0 million. As per the press release, Q3 earnings came out yesterday.
    • Sunshine Biopharma (NASDAQ:SBFM) stock declined by 10.1% to $0.17. The market value of their outstanding shares is at $4.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDRX
    $ENSC
    $GTHX
    $ITRM

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    KalVista Pharmaceuticals Inc.
    $KALV
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/7/2025$30.00Buy
    TD Cowen
    KalVista Pharmaceuticals Inc.
    $KALV
    12/18/2024$22.00Buy
    BofA Securities
    Beyond Air Inc.
    $XAIR
    6/25/2024Buy → Neutral
    BTIG Research
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    8/12/25 7:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    SEC Filings

    View All

    SEC Form 10-K filed by Medicinova Inc

    10-K - MEDICINOVA INC (0001226616) (Filer)

    3/10/26 5:15:50 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/9/26 4:05:28 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/6/26 4:16:02 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by KalVista Pharmaceuticals Inc.

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    3/10/26 6:47:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 11,250 shares and sold $83,345 worth of shares (5,354 units at $15.57), increasing direct ownership by 4% to 138,983 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:46 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $156,197 worth of shares (10,034 units at $15.57), increasing direct ownership by 3% to 442,883 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

    GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. ("XTL") relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its ter

    3/10/26 7:30:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

    March 9, 2026 Biodexa Announces Support for Life's a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated

    3/9/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Financials

    Live finance-specific insights

    View All

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

    DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Ac

    11/7/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa

    11/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $ENSC
    $GTHX
    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care